患者在選擇慢性淋巴細胞白血病治療時的核心優先事項
美國現有約13萬慢性淋巴細胞白血病(CLL)患者,每年新診斷近2萬例。研究採用離散選擇實驗(DCE)調查384例自報醫生診斷CLL的患者,評估其對療效、不良事件、給藥方式及自付費用的偏好。患者最重視更長的無進展生存期(PFS),但不良事件風險亦重要;納入費用後,大量患者改變選擇。作者建議醫生選擇治療策略時探討患者對不同治療特徵的偏好,包括獲益-風險權衡與自付費用。
要点
- 患者對CLL治療屬性的相對重要性最高為更長的無進展生存期(PFS)。
- 不良事件風險亦重要,需顯著額外PFS才能抵消患者對不良事件加重的接受度。
- 納入自付費用後,大量患者改變了兩種治療間的選擇。
核心结论
- 患者對CLL治療屬性的相對重要性最高為更長的無進展生存期(PFS),但不良事件風險亦重要,需顯著額外PFS才能抵消患者對不良事件加重的接受度。
- 納入自付費用後,大量患者改變了兩種治療間的選擇。
- 作者建議醫生選擇最佳治療策略時探討患者對不同治療特徵的偏好,包括獲益-風險權衡與自付費用。
研究设计与样本
- 採用離散選擇實驗(DCE)調查患者對治療屬性的偏好及自付費用對選擇的影響。
- 每個假設治療由5個屬性定義,包括療效、不良事件及給藥方式,各屬性有預設水平。
- 患者倡導組織招募384例自報醫生診斷的CLL患者完成在線調查。
主要发现
- 受訪者對更長的無進展生存期(PFS)賦予最高的相對重要性。
- 不良事件風險亦重要,需顯著額外PFS才能抵消患者對不良事件加重的接受度。
- 納入費用後,大量患者改變了兩種治療間的選擇。
临床怎么用
- 作者建議醫生選擇最佳治療策略時探討患者對不同治療特徵的偏好,包括獲益-風險權衡與自付費用。
局限性
- 原文未報告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Currently, in the United States, 130 000 people live with chronic lymphocytic leukemia (CLL), and almost 20 000 new cases of CLL are diagnosed each year. Little is known about the value patients place upon the attributes of available CLL treatments, which vary in efficacy, side effects, and mode of administration. We used a discrete-choice experiment (DCE) to investigate patients' preferences for treatment attributes and the impact of out-of-pocket cost on patients' choices. DCE surveys pose a series of choices between hypothetical treatment options, each defined by a set of attributes, and the responses provide quantitative estimates of the average relative preferences for treatment attribute. Each hypothetical treatment in this survey was defined by 5 attributes with predefined levels for efficacy, adverse events, and mode administration. A patient advocacy organization recruited 384 patients with a self-reported physician diagnosis of CLL to complete the online survey. Respondents placed the highest relative importance on longer progression-free survival (PFS). However, the risk of adverse events also was important, as significant additional PFS was needed to offset patients' acceptance of worsening adverse events. A supplemental question with 2 treatments and varying costs was included to assess the impact of cost on choice. When costs were included, a large proportion of patients changed their choices between the 2 treatments. Given the available treatments and the high cost of some treatments, physicians may want to explore their patients' preferences for different treatment features, including benefit-risk tradeoffs and out-of-pocket cost, when selecting the best treatment strategies for patients.
引用
- Mansfield C, Masaquel A, Sutphin J, et al. Patients' priorities in selecting chronic lymphocytic leukemia treatments. Blood Adv. 2017. PMID: 29296865. doi:10.1182/bloodadvances.2017007294
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。